title: Serum endothelial monocyte-activating polypeptide-II: a novel biomarker in patients with non-small-cell lung cancer.
abstract: BACKGROUND
  Endothelial monocyte-activating polypeptide-II (EMAP-II) is a proinflammatory cytokine with antiangiogenic properties. Serum EMAP-II levels have not been investigated previously in non-small-cell lung cancer (NSCLC). The aim of this study was to examine the relationship between serum EMAP-II levels and clinicopathologic features, including prognosis, in patients with NSCLC.
  
  
  METHODS
  We measured serum EMAP-II levels in 30 healthy control subjects and 48 patients with untreated NSCLC by enzyme linkedimmunosorbent assay.
  
  
  RESULTS
  Patients with NSCLC had significantly higher serum EMAP-II levels than did the control group (492 pg/mL +/- 1126 pg/mL vs. 266 pg/mL +/- 1013 pg/mL; P = .015). No significant association was found between serum EMAP-II levels and various clinicopathologic features (age, smoking history, performance status, histopathology, tumor stage, lymph node stage, or distant metastasis). Median survival time was 10.13 months (range, 2-53.8 months). The high-EMAP-II (>or= 100 pg/mL) group had a shorter survival compared with the low-EMAP-II (< 100 pg/mL) group (P = .023), and the serum EMAP-II level was still an important predictor of survival in a multivariate analysis, along with disease stage.
  
  
  CONCLUSIONS
  Our results showed that serum EMAP-II levels are significantly higher in patients with NSCLC than in healthy subjects and suggest it is of potential prognostic value.
authors.affiliation: Pulmonary Diseases Department, Ankara University School of Medicine, Ankara, Turkey. elifsen2001@yahoo.com
authors.forename: Elif
authors.initials: E
authors.lastname: Sen
authors.forename: Fusun
authors.initials: F
authors.lastname: Ulger
authors.forename: Akin
authors.initials: A
authors.lastname: Kaya
authors.forename: Nejat
authors.initials: N
authors.lastname: Akar
authors.forename: Ugur
authors.initials: U
authors.lastname: Gonullu
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000175:diagnosis*; D016207:Cytokines / Q000097:blood* / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009363:Neoplasm Proteins / Q000097:blood* / Q000378:metabolism; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D016601:RNA-Binding Proteins / Q000097:blood* / Q000378:metabolism; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D016207:Cytokines; D009363:Neoplasm Proteins; D016601:RNA-Binding Proteins; C077219:small inducible cytokine subfamily E, member 1